Yes, so this morning I discussed and presented the results of the crossover analysis of the peak trial in advanced GIST. And the trial essentially randomized patients that had received prior therapy with imatinib to either receive bosutinib plus sunitinib or sunitinib alone. The primary analysis, the pivotal analysis from the trial were presented at ASCO earlier this year by Dr...
Yes, so this morning I discussed and presented the results of the crossover analysis of the peak trial in advanced GIST. And the trial essentially randomized patients that had received prior therapy with imatinib to either receive bosutinib plus sunitinib or sunitinib alone. The primary analysis, the pivotal analysis from the trial were presented at ASCO earlier this year by Dr. Wagner and the trial met the primary endpoint showing a significant benefit for the combination of bosutinib and sunitinib compared to sunitinib alone in terms of median progression-free survival. The analysis presented at ESMO today essentially looked at the outcome and safety of using the combination in patients that had experienced disease progression on sunitinib alone within the trial. So patients on sunitinib with disease progression were allowed to receive the combination therapy and the trial showed that the use of the combination schedule following sunitinib alone was beneficial both in terms of progression-free survival and response rate but was also comparable in terms of the safety profile to the pivotal portion of the trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.